HERG Screening Market Analysis and Global Forecast 2023-2033

HERG Screening Market Overview

The HERG Screening Market Size is expected to reach USD 6.35 Billion by 2033. The HERG Screening Market industry size accounted for USD 1.94 Billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 14.10% from 2023 to 2033. The HERG Screening Market refers to the market for technologies and services used to evaluate the potential of compounds to inhibit the human ether-a-go-go-related gene (HERG) potassium channel. This gene is important because its inhibition can lead to cardiac arrhythmias, a potentially fatal condition. HERG screening is a critical part of the drug development process, as identifying and mitigating the risk of HERG channel inhibition early can prevent adverse cardiac effects in later stages of drug development or after the drug is on the market.

The HERG Screening Market is an essential component of the broader pharmaceutical safety assessment market, helping to ensure that new drugs are both effective and safe for human use. It’s driven by Increasing regulatory scrutiny of drug safety and advancements in HERG screening technologies.

Global HERG Screening Market Synopsis

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on the HERG Screening Market. The pandemic led to disruptions in global supply chains, affecting the availability of reagents, instruments, and consumables needed for HERG screening. During the height of the pandemic, many pharmaceutical and biotech companies shifted their focus towards developing COVID-19 therapeutics and vaccines. This shift led to a temporary reduction in other drug development activities, including HERG screening for non-COVID-19 drugs. The pandemic highlighted the importance of drug safety and the need for robust screening processes, including HERG screening, to ensure that new therapeutics do not have adverse cardiac effects. As the initial wave of the pandemic subsided, drug development activities gradually resumed, leading to a recovery in demand for HERG screening services and technologies. The pandemic also spurred innovation in drug development processes, which could drive future growth in the market. The pandemic fostered greater collaboration between pharmaceutical companies, CROs, and academic institutions. Many organizations opted to outsource HERG screening to specialized CROs to ensure continuity and leverage expertise, which could lead to increased demand for screening services.

HERG Screening Market Dynamics

The major factors that have impacted the growth of HERG Screening Market are as follows:

Drivers:

Ø  Technological Advancements

Innovations in screening technologies, such as automated and high-throughput screening systems, enhance the efficiency, accuracy, and reliability of HERG assays. These advancements make HERG screening more accessible and cost-effective for pharmaceutical companies. The increasing investment in pharmaceutical and biotechnology R&D to develop new drugs drives the demand for HERG screening. As companies explore novel therapeutics, the need to assess cardiac safety early in the development process becomes essential. Many pharmaceutical and biotechnology companies are outsourcing HERG screening to specialized contract research organizations (CROs) to leverage their expertise and reduce costs. This trend drives demand for HERG screening services as companies focus on core competencies and rely on CROs for specialized tasks.

Restraint:

• Perception of High Costs of Screening Technologies and Technical Complexity

The initial investment required for acquiring sophisticated screening equipment and assays can be substantial. This can be a barrier for smaller pharmaceutical and biotechnology companies with limited budgets. Developing and validating HERG screening assays can be technically challenging, requiring specialized expertise and experience. This complexity can slow down adoption and implementation, especially in organizations lacking in-house expertise.

Opportunity:

⮚      Expansion of Drug Development Pipelines

The exploration of new therapeutic areas, such as personalized medicine and gene therapy, creates a need for specialized HERG screening to ensure the safety of novel drug candidates. The trend of repurposing existing drugs for new therapeutic indications requires thorough safety assessments, including HERG screening, to evaluate potential cardiotoxicity. The growing focus on personalized medicine presents opportunities for HERG screening to play a critical role in ensuring the safety of drugs tailored to specific patient populations.

HERG Screening Market Segment Overview

By Type

Based on Type, the market is segmented based on Mutant KCNH2 and Gene KCNH2. Gene KCNH2 segment dominated the market. This channel is especially important for the generation and transmission of electrical impulses as it is in charge of removing positively charged potassium atoms from the cells. This is so that it can move the atoms of potassium. The KCNH2 gene is in charge of controlling and supplying the necessary instructions for the production of potassium channels. The main reason causing the ultimate emergence of cardiac arrhythmia was the KCNH2 mutation.

By Ion Channel

Based on Ion Channel, the market segment has been divided into Voltage Gated and Ligand Gated. Voltage Gated segment dominated the HERG Screening market.The members of the voltage-gated ion channel family that regulate the open and closed states of the cell membrane potential include Na+, Ca+, and K+. The ionic gradients required for regular cell activity are maintained by these channels in a variety of cell types, including neurons, heart muscle, and skeletal muscle. The movement of ions across cell membranes is tightly regulated by these channels.

By Application

Based on Application, the market segment has been divided into Antiarrhythmic, Antipsychotic, Antibiotics and Others. Antiarrhythmic segment dominated the market. Antiarrhythmic medications are used to treat symptomatic tachycardias and premature beats. These can be administered intravenously in an emergency or orally for long-term treatment. These drugs either prevent aberrant pacemaker tissue firing or reduce the speed at which impulses are transmitted in tissues that conduct too quickly or engage in reentry. The use of these assays for arrhythmia treatment, scientific investigations into the safety and effectiveness of HERG screening, and an increase in cardiovascular diseases globally are all factors propelling the market’s growth.

Global HERG Screening Market Regional Analysis

Based on region, the global HERG Screening Market has been divided into North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America. North America is projected to dominate the use of the HERG Screening Market followed by the Asia-Pacific and Europe regions.

Global HERG Screening North America Market

North America holds a dominant position in the HERG Screening Market. North America is a dominant region in the HERG Screening Market, primarily due to the presence of a large number of pharmaceutical and biotechnology companies, advanced healthcare infrastructure, and significant investment in R&D. The stringent regulatory requirements set by agencies like the FDA drive the demand for comprehensive HERG screening to ensure drug safety and the region benefits from technological advancements and high adoption of automated and high-throughput screening systems.

Global HERG Screening Asia-Pacific Market

The Asia-Pacific region has indeed emerged as the fastest-growing market for the HERG Screening Market industry. The Asia-Pacific region is experiencing rapid growth in the HERG Screening Market due to increasing pharmaceutical R&D activities, especially in countries like China, India, and Japan. The growing focus on drug discovery and development in emerging markets, coupled with supportive government initiatives, is driving market expansion and the region is becoming a hub for outsourcing drug development processes, including HERG screening, due to cost advantages and the availability of skilled talent.

Competitive Landscape

The global HERG Screening Market is highly competitive, with numerous players offering a wide range of software solutions. The competitive landscape is characterized by the presence of established companies, as well as emerging startups and niche players. To increase their market position and attract a wide consumer base, the businesses are employing various strategies, such as product launches, and strategic alliances.

Prominent Players:

• Charles River Laboratories
• Eurofins Scientific
• Merck KGaA
• Cyprotex Limited
• BSYS GmbH
• Creative bioarray
• Metrion biosciences
• CREATIVE BIOARRAY
• ABCAM PLC.
• Aurora Biomed

Scope of the Report

Global HERG Screening Market, by Type

• Mutant KCNH2
• Gene KCNH2

Global HERG Screening Market, by Ion Channel

• Voltage Gated
• Ligand Gated

Global HERG Screening Market, by Application

• Antiarrhythmic
• Antipsychotic
• Antibiotics
• Others

Global HERG Screening Market, by Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Benelux
  • Nordic
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Indonesia
  • Austalia
  • Malaysia
  • India
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of Middle East & Africa

 

Parameters	Indicators
Market Size	2033: $6.35 Billion
CAGR	14.10% CAGR (2023-2033)
Base year	2022
Forecast Period	2023-2033
Historical Data	2021
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Key Segmentations	Type, Ion Channel, Application
Geographies Covered	North America, Europe, Asia-Pacific, Latin America, Middle East, Africa
Key Vendors	Charles River Laboratories, Eurofins Scientific, Merck KGaA, Cyprotex Limited, BSYS GmbH, Creative bioarray, Metrion biosciences, CREATIVE BIOARRAY, ABCAM PLC. And Aurora Biomed
Key Market Opportunities	• Expansion of Drug Development Pipelines • Focus on Drug Repurposing
Key Market Drivers	• Technological Advancements • Rising Pharmaceutical R&D Activities

REPORT CONTENT BRIEF:

• High-level analysis of the current and future HERG Screening Market trends and opportunities
• Detailed analysis of current market drivers, restraining factors, and opportunities in the future
• HERG Screening Market historical market size for the year 2021, and forecast from 2023 to 2033
• HERG Screening Market share analysis at each product level
• Competitor analysis with detailed insight into its product segment, Government & Defense strength, and strategies adopted.
• Identifies key strategies adopted including product launches and developments, mergers and acquisitions, joint ventures, collaborations, and partnerships as well as funding taken and investment done, among others.
• To identify and understand the various factors involved in the global HERG Screening Market affected by the pandemic
• To provide a detailed insight into the major companies operating in the market. The profiling will include the Government & Defense health of the company’s past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.